Etomoxir: Difference between revisions
From Bioblast
No edit summary |
No edit summary |
||
| Line 10: | Line 10: | ||
== Application in [[HRFR]] == | == Application in [[HRFR]] == | ||
:::: '''Eto (Etomoxir):''' ((+)-Etomoxir sodium salt hydrate); Sigma Aldrich; E-1905; storage: 2-8 °C; FW= 338.76 | ::::*'''Eto (Etomoxir):''' ((+)-Etomoxir sodium salt hydrate); Sigma Aldrich; E-1905; storage: 2-8 °C; FW= 338.76 | ||
:::: '''Caution:''' Store tightly sealed, protected from exposure to light. Acute toxicity (oral, dermal, inhalation. Dust mask or eyeshields, faceshields and gloves are recommended by the preparation. | ::::*'''Caution:''' Store tightly sealed, protected from exposure to light. Acute toxicity (oral, dermal, inhalation. Dust mask or eyeshields, faceshields and gloves are recommended by the preparation. | ||
Revision as of 17:51, 22 August 2017
- high-resolution terminology - matching measurements at high-resolution
Etomoxir
Description
Etomoxir (Eto; 2[6(4-chlorophenoxy)hexyl]oxirane-2-carboxylate) is an irreversible inhibitor of carnitine palmitoyltransferase-1 (CPT-1) on the outer face of the inner mitochondrial membrane. Eto inhibits the transport of the long-chain fatty acids from the cytosol into the mitochondrial matrix, thereby blocking the formation of acyl carnitines in the cytosol, leading finally to inhibition of the fatty acid oxidation. Of note, in contrast to long-chain fatty acids, the transport of short- and medium chain fatty acids is carnitine-independent.
The commercially available white compound is soluble in water.
Abbreviation: Eto
MitoPedia topics:
Inhibitor
Application in HRFR
- Eto (Etomoxir): ((+)-Etomoxir sodium salt hydrate); Sigma Aldrich; E-1905; storage: 2-8 °C; FW= 338.76
- Caution: Store tightly sealed, protected from exposure to light. Acute toxicity (oral, dermal, inhalation. Dust mask or eyeshields, faceshields and gloves are recommended by the preparation.
